Evidence map›Paper›PMID 35885561›Full record

ReviewDiagnostics (Basel, Switzerland)2022

A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.

Federica De Muzio, Francesca Grassi, Federica Dell'Aversana, Roberta Fusco, Ginevra Danti, Federica Flammia, Giuditta Chiti, Tommaso Valeri, Andrea Agostini, Pierpaolo Palumbo and 8 more

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Federica De MuzioDepartment of Medicine and Health Sciences V. Tiberio, University of Molise, 86100 Campobasso, Italy.
Francesca GrassiDivision of Radiology, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy.
Federica Dell'AversanaDivision of Radiology, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy.
Roberta FuscoMedical Oncology Division, Igea SpA, 80013 Naples, Italy.
Ginevra DantiDivision of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy.ORCID 0000-0002-7109-8119
Federica FlammiaDivision of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy.
Giuditta ChitiDivision of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy.
Tommaso ValeriDepartment of Clinical Special and Dental Sciences, University Politecnica delle Marche, 60126 Ancona, Italy.
Andrea AgostiniDepartment of Clinical Special and Dental Sciences, University Politecnica delle Marche, 60126 Ancona, Italy.
Pierpaolo PalumboItalian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy.ORCID 0000-0003-1514-0092
Federico BrunoItalian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy.ORCID 0000-0002-1444-2585
Carmen CutoloDepartment of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy.
Roberta GrassiDivision of Radiology, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy.
Igino SimonettiRadiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via Mariano Semmola, 80131 Naples, Italy.
Andrea GiovagnoniDepartment of Clinical Special and Dental Sciences, University Politecnica delle Marche, 60126 Ancona, Italy.
Vittorio MieleDivision of Radiology, Azienda Ospedaliera Universitaria Careggi, 50134 Florence, Italy.ORCID 0000-0002-7848-1567
Antonio BarileEmergency Radiology, San Salvatore Hospital, Via Lorenzo Natali 1, 67100 L'Aquila, Italy.ORCID 0000-0003-0253-3583
Vincenza GranataRadiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Via Mariano Semmola, 80131 Naples, Italy.ORCID 0000-0002-6601-3221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is the sixth most detected tumor and the third leading cause of tumor death worldwide. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with specific risk factors and a targeted population. Imaging plays a major role in the management of HCC from screening to post-therapy follow-up. In order to optimize the diagnostic-therapeutic management and using a universal report, which allows more effective communication among the multidisciplinary team, several classification systems have been proposed over time, and LI-RADS is the most utilized. Currently, LI-RADS comprises four algorithms addressing screening and surveillance, diagnosis on computed tomography (CT)/magnetic resonance imaging (MRI), diagnosis on contrast-enhanced ultrasound (CEUS) and treatment response on CT/MRI. The algorithm allows guiding the radiologist through a stepwise process of assigning a category to a liver observation, recognizing both major and ancillary features. This process allows for characterizing liver lesions and assessing treatment. In this review, we highlighted both major and ancillary features that could define HCC. The distinctive dynamic vascular pattern of arterial hyperenhancement followed by washout in the portal-venous phase is the key hallmark of HCC, with a specificity value close to 100%. However, the sensitivity value of these combined criteria is inadequate. Recent evidence has proven that liver-specific contrast could be an important tool not only in increasing sensitivity but also in diagnosis as a major criterion. Although LI-RADS emerges as an essential instrument to support the management of liver tumors, still many improvements are needed to overcome the current limitations. In particular, features that may clearly distinguish HCC from cholangiocarcinoma (CCA) and combined HCC-CCA lesions and the assessment after locoregional radiation-based therapy are still fields of research.

Indexed as

diagnosisLI-RADSliver

Identifiers

PMID35885561
PMCPMC9319674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.